Pharmacoeconomic Review Report : Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited)

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Physical Description:

1 online resource (37 pages).

Place of Publication:

Calgary, AB, CA: Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

Ocrelizumab (Ocrevus) is a recombinant humanized monoclonal antibody that selectively targets and depletes CD20-expressing B-cells, which are thought to contribute to the inflammatory and neurodegenerative pathogenesis of multiple sclerosis (MS). Ocrelizumab is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS), and was previously reviewed by CADTH. The CADTH Canadian Drug Expert Committee recommended that ocrelizumab be listed for RRMS based on the condition of a price reduction of at least 50%. This submission relates to an application to Health Canada for an indication relating to the treatment of adult patients with primary progressive multiple sclerosis (PPMS) to delay disease progression and reduce deterioration in walking speed.

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of the Manufacturer's Pharmacoeconomic Submission

Manufacturer's Base Case

Summary of Manufacturer's Sensitivity Analyses

Limitations of Manufacturer's Submission

CADTH Common Drug Review Reanalyses

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Additional Information

Appendix 3. Summary of Other Health Technology Assessment Reviews of Drug

Appendix 4. Reviewer Worksheets

References.

OCLC:

1028583040

Publisher Number:

10095246 CaOOCEL (Public Documents)